Medicamen Organics Q4 FY25 Share Price & Earnings Call Analysis
- Market cap
- ₹38 Cr
- ROE
- -13.80%
- Price to sales
- 1.73
- Debt to equity
- 0.50
- 52W high / low
- ₹38.0 / ₹19.1
- EBITDA margin
- -16.61%
- Net profit margin
- -18.63%
- Promoter holding
- 54.89%
- Sales (last year)
- ₹22 Cr
Incorporated in 1995, Medicamen Organics Ltd develops, manufactures, and distributes a broad range of pharmaceutical dosages including generic dosage[1]
Guidance scorecard · Q4 FY25 call
What Medicamen Organics Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology
Pharmaceuticals & Biotechnology
RevenueQ4 FY25 call
40%+- Medicamen Organics targets revenues of INR 60-65 crores for FY '26.
- The company plans a 60% CAGR in revenue over the next three years.
- Expansion includes a 20% capacity increase at the Haridwar facility.
- Nepal facility expected to contribute from FY '27 onwards, with optimum potential above INR 400 crores.
- Focus on growing export markets, aiming for 75% export and 25% domestic revenue mix.
- Plans to register around 120 products in Africa over the next two years.
- Growth driven by diversification into personal care/cosmetics with INR 15 crores revenue targeted for FY '26.
2 more points from Medicamen Organics Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ4 FY25 call
FlatSee what Medicamen Organics Ltd said on margins — free account, 30 seconds.
CapexQ4 FY25 call
Planned- INR9 crores investment planned to acquire 30% stake in Medi Hub Organic Limited, Nepal, through subsidiary Grande Etoile Pharmaceuticals Limited.
- Expansion of Haridwar manufacturing facility by 20% underway to enhance operational efficiency and scale production.
- Plans to construct an EU-approved manufacturing facility for better control over production, targeted commercialization starting around 15 months from now, with first-year revenue potential of INR50 crores.
- No current plans for fundraising; expansions funded through internal accruals and INR3 crores raised via convertible warrants from Promoter Group.
2 more points from Medicamen Organics Ltd's call on capex
Create a free account to keep reading this call
FundraisingQ4 FY25 call
None plannedSee what Medicamen Organics Ltd said on fundraising — free account, 30 seconds.
Order bookQ4 FY25 call
- Current orders in hand with the East Africa subsidiary stand at around $125,000.
- An advance payment of $50,000 has been received from the subsidiary.
- The first shipment from the East Africa operations is scheduled for this month.
- Post initial shipment, similar subsequent orders are expected.
- The company is preparing for a good influx of orders this year, supported by 20% capacity expansion at the primary facility.
2 more points from Medicamen Organics Ltd's call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹556 Cr | 22.1 | |
| 2 | 40%+ | Up 0–2% | ₹215 Cr | 22.2 | |
| 3 | 40%+ | Flat | ₹16,144 Cr | — | |
| 4 | 40%+ | Flat | ₹6,072 Cr | 48.0 | |
| 5 | Medicamen Organics LtdThis stock | 40%+ | Flat | ₹40 Cr | — |
| 6 | 20–40% | Up 2%+ | ₹50,220 Cr | 43.8 |
Sign up free to see every company in the sector ranking and track Medicamen Organics Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Medicamen Organics Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Medicamen Organics Ltd
Quarterly Results
Quarter-by-quarter operating performance
Financials of Medicamen Organics Ltd
Profit & Loss
Annual income statement trend
| Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|
| Sales + | 25.27 | 38.19 | 39.43 |
| Expenses + | 20.53 | 31.58 | 32.16 |
| Operating Profit | 4.74 | 6.61 | 7.27 |
| OPM % | 18.76% | 17.31% | 18.44% |
| Other Income + | 1.07 | 0.10 | 0.11 |
| Interest | 0.65 | 0.54 | 0.62 |
| Depreciation | 0.72 | 0.74 | 0.78 |
| Profit before tax | 4.44 | 5.43 | 5.98 |
| Tax % | 40.77% | 25.41% | |
| Net Profit + | 2.62 | 4.05 | 4.58 |
| EPS in Rs | 3.05 | 3.46 | 3.91 |
| Dividend Payout % | 0.00% | 0.00% |
Financials of Medicamen Organics Ltd
Balance Sheet
Capital structure and asset base
| Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|
| Equity Capital | 8.60 | 11.70 | 11.70 |
| Reserves | 6.66 | 18.43 | 20.92 |
| Borrowings + | 12.66 | 12.35 | 15.67 |
| Other Liabilities + | 10.52 | 16.73 | 12.86 |
| Total Liabilities | 38.44 | 59.21 | 61.15 |
| Fixed Assets + | 10.35 | 10.13 | 12.79 |
| CWIP | 0.15 | 2.22 | 0.36 |
| Investments | 0.00 | 0.00 | 0.00 |
| Other Assets + | 27.94 | 46.86 | 48.00 |
| Total Assets | 38.44 | 59.21 | 61.15 |
Financials of Medicamen Organics Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Cash from Operating Activity + | -3.66 | -4.54 |
| Cash from Investing Activity + | -0.34 | -2.35 |
| Cash from Financing Activity + | 4.01 | 10.47 |
| Net Cash Flow | 0.01 | 3.58 |
| Free Cash Flow | -4.01 | -6.99 |
| CFO/OP | -73% | -67% |
Financials of Medicamen Organics Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Debtor Days | 241.21 | 247.06 |
| Inventory Days | 244.39 | 228.39 |
| Days Payable | 281.81 | 356.77 |
| Cash Conversion Cycle | 203.80 | 118.69 |
| Working Capital Days | 74.24 | 135.14 |
| ROCE % | 16.88% |
Continue your research
What Medicamen Organics Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
- Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
- Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
- Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY